发明名称 HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
摘要 <p>C XNRPonhnD)C(AARW 2"'>_1 I)OC-9'252 1.' -38 A BST RA CT The present invention relates to an lLA-A*l 101-restricted WTI peptide, specifically, a peptide comprising an amino acid ;equencc consisting of 9 contiguous amino acids from a WT1 protein, wherein the peptide has an ability to bind to an HlLA-A*l 101 molecule, and has an ability to induce a CTL. The present invention also relates to a peptide dimer having an ability to bind to an HlIA-A*I 101 molecule and having an ability to induce a CTL, in which two peptide monomers each comprising an amino acid sequence consisting of 9 contiguous amino acids from a WTI protein and comprising at least one cysteine residue are bound to each other through a disulfide bond. Furthermore, the present invention relates to a polynuclcotide encoding the peptide, a pharmaceutical composition for the treatment and/or prevention of a cancer comprising the same and the like.</p>
申请公布号 AU2012227350(C1) 申请公布日期 2015.11.12
申请号 AU20120227350 申请日期 2012.09.26
申请人 INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. 发明人 SUGIYAMA, HARUO
分类号 C12N15/12;A61K31/7088;A61K38/00;A61K48/00;A61P35/00;A61P35/02;C07K14/82;C12Q1/02;G01N33/574 主分类号 C12N15/12
代理机构 代理人
主权项
地址